Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study

被引：0

作者：

Baldacci, Simon ^{[1
]}

Mazieres, Julien ^{[2
]}

Tomasini, Pascale ^{[3
]}

Girard, Nicolas ^{[4
]}

Guisier, Florian ^{[5
]}

Valette, Clarisse Audigier ^{[6
]}

Monnet, Isabelle ^{[7
]}

Wislez, Marie ^{[8
]}

Perol, Maurice ^{[9
]}

Do, Pascal ^{[10
]}

Dansin, Eric ^{[11
]}

Leduc, Charlotte ^{[12
]}

Leprieur, Etienne Giroux ^{[13
]}

Moro-Sibilot, Denis ^{[14
]}

Kherrouche, Zoulika ^{[15
]}

Labreuche, Julien ^{[16
]}

Cortot, Alexis ^{[1
]}

机构：

[1] Univ Lille, CHU Lille, Serv Pneumol & Oncol Thorac, Lille, France

[2] Toulouse Univ Hosp, Toulouse, France

[3] AP HM, Dept Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[4] Hosp Civils Lyon, Louis Pradel Hosp, Resp Med, Lyon, France

[5] Rouen Univ Hosp, Rouen, France

[6] Ctr Hosp St Musse, Toulon, France

[7] Ctr Hosp Intercommunal Creteil, Creteil, France

[8] Hop Tenon, Serv Pneumol, AP HP, Paris, France

[9] Ctr Leon Berard, Grp Thorac & Orl, Lyon, France

[10] Ctr Reg Lutte Contre Le Canc Francois Baclesse, Caen, France

[11] Ctr Oscar Lambret, Lille, France

[12] CHU Strasbourg, Strasbourg, France

[13] Hop Ambroise Pare, AP HP, Boulogne, France

[14] Pole Thorax & Vaisseaux, Unite Oncol Thorac, Serv Pneumol, Grenoble, France

[15] Univ Lille, CNRS, Inst Pasteur Lille, Inst Biol Lille,Umr 8161, Lille, France

[16] Univ Lille, Ea 2694, Lille, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

MET amplification; non-small cell lung cancer; EGFR mutation; TKI resistance;

D O I：

10.1016/j.jtho.2016.11.1718

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-051

引用

页码：S1219 / S1220

页数：2

共 50 条

[21] Can We Avoid Using Chemotherapy in Managing Acquired Resistance of EGFR-Mutated NSCLC?
Prempree, Thongbliew
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1260 - S1261
[22] FDG-PET/CT in Patients with EGFR-Mutated NSCLC Treated with TKI. Can We Identify Early Lesions at Higher Risk of Progression?
Petyt, Gegory
Bellevre, Dimitri
Adens, Amaury
Lahousse, Helene
Collet, Guillaume
Hossein-Foucher, Claude
Baldacci, Simon
Dhalluin, Xavier
Willemin, Marie-Capucine
Baranzelli, Anne
Scherpereel, Arnaud
Cortot, Alexis
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S553 - S553
[23] Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
Furugaki, Koh
Iwai, Toshiki
Moriya, Yoichiro
Harada, Naoki
Fujimoto-Ouchi, Kaori
LUNG CANCER, 2014, 83 (01) : 44 - 50
[24] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D. Zheng
X. Ye
M. Z. Zhang
Y. Sun
J. Y. Wang
J. Ni
H. P. Zhang
L. Zhang
J. Luo
J. Zhang
L. Tang
B. Su
G. Chen
G. Zhu
Y. Gu
J. F. Xu
Scientific Reports, 6
[25] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
Zheng, D.
Ye, X.
Zhang, M. Z.
Sun, Y.
Wang, J. Y.
Ni, J.
Zhang, H. P.
Zhang, L.
Luo, J.
Zhang, J.
Tang, L.
Su, B.
Chen, G.
Zhu, G.
Gu, Y.
Xu, J. F.
SCIENTIFIC REPORTS, 2016, 6
[26] Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
Hackner, Klaus
Buder, Anna
Hochmair, Maximilian J.
Strieder, Matthaeus
Grech, Christina
Fabikan, Hannah
Burghuber, Otto C.
Errhalt, Peter
Filipits, Martin
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
[27] The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases
Han, Huan
Tang, Hong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study)
Veerman, G. D. M.
Steendam, C. M. J.
Koolen, S. L.
Oomen-de Hoop, E.
Dingemans, A-M. C.
Aerts, J. G. J. V.
Mathijssen, R. H.
ANNALS OF ONCOLOGY, 2020, 31 : S861 - S862
[29] HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
Mok, Tony
Jaenne, Pasi A.
Nishio, Makoto
Novello, Silvia
Reck, Martin
Steuer, Conor
Wu, Yi-Long
Fougeray, Ronan
Fan, Pang-Dian
Meng, Jie
Sternberg, David W.
Esker, Stephen
Yu, Helena A.
FUTURE ONCOLOGY, 2024, 20 (15) : 969 - 980
[30] Erlotinib/gefitinibDevelopment of resistance in EGFR-mutated NSCLC patients: 8 case reports
Reactions Weekly, 2015, 1540 (1) : 130 - 130

← 1 2 3 4 5 →